Roosendaal G - Search Results

1

High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients.

Mauser-Bunschoten EP, Zaaijer HL, van Drimmelen AA, de Vries S, Roosendaal G, van den Berg HM, Lelie PN. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Vox Sang. 1998;74(4):225-7. Vox Sang. 1998. PMID: 9691402 Clinical Trial.

2

Hepatitis C infection and viremia in Dutch hemophilia patients.

Mauser-Bunschoten EP, Bresters D, van Drimmelen AA, Roosendaal G, Cuypers HT, Reesink HW, van der Poel CL, van den Berg HM, Lelie PN. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. J Med Virol. 1995 Mar;45(3):241-6. doi: 10.1002/jmv.1890450302. J Med Virol. 1995. PMID: 7539831

3

Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A.

Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Roosendaal G, Briët E, van den Berg HM. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Thromb Haemost. 1994 Jun;71(6):703-6. Thromb Haemost. 1994. PMID: 7974335 Free article. Clinical Trial.

4

Risk of hepatitis A in Dutch hemophilia patients.

Mauser-Bunschoten EP, Zaaijer HL, van Drimmelen AA, van den Berg HM, Roosendaal G, Lelie PN. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Thromb Haemost. 1995 Aug;74(2):616-8. Thromb Haemost. 1995. PMID: 8584994

5

Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C.

Mauser-Bunschoten EP, Damen M, Reesink HW, Roosendaal G, Chamuleau RA, van den Berg HM. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Ann Intern Med. 1996 Aug 15;125(4):297-9. doi: 10.7326/0003-4819-125-4-199608150-00007. Ann Intern Med. 1996. PMID: 8678393 Clinical Trial.

6

Low-dose immune tolerance therapy: the van creveld model.

Mauser-Bunschoten EP, Roosendaal G, van den Berg HM. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Vox Sang. 1996;70 Suppl 1:66-7. Vox Sang. 1996. PMID: 8869472 No abstract available.

7

Hepatitis G virus RNA and hepatitis G virus-E2 antibodies in Dutch hemophilia patients in relation to transfusion history.

Mauser-Bunschoten EP, Damen M, Zaaijer HL, Sjerps M, Roosendaal G, Lelie PN, Cuypers HT, van den Berg HM. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Blood. 1998 Sep 15;92(6):2164-8. Blood. 1998. PMID: 9731076 Free article.

8

Progression to AIDS in relation to clinical factors and clotting product consumption. A 14-year follow-up of a cohort of 52 Dutch HIV-1-infected haemophilic patients.

Roosendaal G, van der Schouw Y, Mauser-Bunschoten E, Borleffs J, van den Berg H. Roosendaal G, et al. Vox Sang. 1998;75(4):261-6. Vox Sang. 1998. PMID: 9873260 Clinical Trial.

9

Product choice and haemophilia treatment in the Netherlands.

Mauser-Bunschoten EP, Roosendaal G, van den Berg HM. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Haemophilia. 2001 Jan;7(1):96-8. doi: 10.1046/j.1365-2516.2001.00464.x. Haemophilia. 2001. PMID: 11136388

10

Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.

Mauser-Bunschoten EP, van der Bom JG, Bongers M, Twijnstra M, Roosendaal G, Fischer K, van den Berg HM. Mauser-Bunschoten EP, et al. Among authors: roosendaal g. Haemophilia. 2001 Jul;7(4):364-8. doi: 10.1046/j.1365-2516.2001.00513.x. Haemophilia. 2001. PMID: 11442640

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page